Targeting PFKL with penfluridol inhibits glycolysis and suppresses esophageal cancer tumorigenesis in an AMPK/FOXO3a/BIM-dependent manner

As one of the hallmarks of cancer, metabolic reprogramming leads to cancer progression, and targeting glycolytic enzymes could be useful strategies for cancer therapy. By screening a small molecule library consisting of 1320 FDA-approved drugs, we found that penfluridol, an antipsychotic drug used t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Cancan, Yu, Xiaomei, Liang, Yiyao, Zhu, Yidong, He, Yan, Liao, Long, Wang, Dingkang, Yang, Yanming, Yin, Xingfeng, Li, Ang, He, Qingyu, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069409/
https://www.ncbi.nlm.nih.gov/pubmed/35530161
http://dx.doi.org/10.1016/j.apsb.2021.09.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9069409/
https://www.ncbi.nlm.nih.gov/pubmed/35530161
http://dx.doi.org/10.1016/j.apsb.2021.09.007

Ejemplares similares